Engineered Bacteriocin Tail Fibers for Antibiotic-Resistant Pathogen Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibacterial agents are ineffective against antibiotic-resistant bacterial pathogens, particularly Pseudomonas aeruginosa, which poses a significant threat due to rising resistance and limited diagnostic and therapeutic options.
Innovation Solution
Engineered high molecular weight bacteriocins, such as modified R-type pyocins, with altered tail fibers and receptor binding domains, are developed to target specific bacterial strains, including those resistant to conventional antibiotics, by modifying the amino acid sequence or incorporating heterologous sequences from bacteriophage tail proteins to broaden their bactericidal spectrum.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antibiotics are used, then they can treat common bacterial infections, but they become ineffective against antibiotic-resistant bacterial pathogens
Solution Approach 1:
The patent modifies the amino acid sequence of tail fiber proteins in bacteriocins to alter their binding specificity and affinity for bacterial receptors. This parameter change enables the engineered bacteriocins to target antibiotic-resistant bacterial strains that conventional antibiotics cannot effectively treat
Solution Approach 2:
The patent creates chimeric tail fiber proteins by combining domains from different bacteriocin or bacteriophage sources. These composite proteins exhibit enhanced binding specificities and broaden the bactericidal spectrum to include multiple resistant bacterial strains
2Adaptability or versatility
If broad-spectrum antibiotics are used, then they can target multiple bacterial strains, but they affect non-target bacteria and contribute to resistance development
Solution Approach 1:
The patent engineers bacteriocins with tailored tail fiber proteins that bind specifically to receptors on target bacterial strains. This localized specificity allows the bacteriocins to eliminate only the intended pathogenic bacteria while leaving beneficial non-target bacteria unaffected
Solution Approach 2:
The patent divides the bacterial infection problem into specific strain targets by creating multiple bacteriocin variants, each with customized tail fiber proteins designed to recognize and bind to specific receptor types found on different resistant bacterial strains
3Reliability
If tail fiber proteins are modified to broaden bactericidal spectrum, then binding specificities and affinities are enhanced, but the complexity of engineering and production increases
Solution Approach 1:
The patent develops a modular engineering platform where standardized domains from bacteriocins and bacteriophages can be combined in different configurations. This universal approach allows multiple bacteriocin variants to be produced using the same core methodology, reducing overall engineering complexity despite the diversity of targets
Solution Approach 2:
The patent uses homologous tail fiber protein sequences from related bacteriocins and bacteriophages as templates for engineering new variants. By copying and adapting existing successful binding domains, the complexity of de novo design is reduced while maintaining effective binding specificities
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These engineered bacteriocins demonstrate enhanced binding specificities and affinities, allowing them to effectively kill targeted bacterial strains, including antibiotic-resistant Pseudomonas aeruginosa, while minimizing impact on non-target bacteria, thus offering a promising solution to the growing antibiotic resistance crisis.
Implementation Method 1
binding specificity and affinity to their cognate binding partners, or receptors, such as those on the surface of bacteria
Implementation Method 2
globular proteins, which proteins can bind and degrade cell surface structures, such as polysaccharides
Data Source
AI summary
Recombinant P4 bacteriophage containing modified tail fibers having a base plate attachment region (BPAR) from a P2 bacteriophage gene H product and a heterologous receptor binding domain (RBD) are disclosed. Methods for the use of the recombinant P4 bacteriophage, such as to detect the presence of a target bacterium in a sample, are also described.